BEL536 / Belenos Biosciences, Keymed Biosciences - LARVOL DELTA

Placebo controlled study testing safety and tolerability of BEL536 in healthy adults. (ANZCTR) - P1 | N=40 | Recruiting | Sponsor: Belenos Biosciences, Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2026

Enrollment open • Trial initiation date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Placebo controlled study testing safety and tolerability of BEL536 in healthy adults. (ANZCTR) - P1 | N=40 | Not yet recruiting | Sponsor: Belenos Biosciences, Inc.

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

…Second Asset BEL536, a First-in-class Long-acting Bispecific Targeting OX40L and IL-13… (Businesswire) - "CTN filed in Australia with target of initiating Phase 1 study in 1Q2026."

New P1 trial • Inflammation